Regeneron Pharmaceuticals Inc (REGN)

373.05
NASDAQ : Health Care
Prev Close 373.05
Day Low/High 0.00 / 0.00
52 Wk Low/High 325.35 / 452.96
Avg Volume 947.70K
Exchange NASDAQ
Shares Outstanding 106.08M
Market Cap 38.30B
EPS 6.20
P/E Ratio 46.88
Div & Yield N.A. (N.A)

Latest News

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Amgen Shows a Bullish Breakout

Amgen Shows a Bullish Breakout

There is more upside to come for this stock.

Chart of the Day: Amgen

There is more upside to come for this stock.

Bullish Momentum for Regeneron

Bullish Momentum for Regeneron

Volatility has calmed down, and there are bullish signs.

Chart of the Week: Regeneron

Volatility has calmed down, and there are bullish signs.

Analysts' Actions -- Evercore, Hasbro, J.C. Penney, Regeneron and More

Analysts' Actions -- Evercore, Hasbro, J.C. Penney, Regeneron and More

Here are Monday's top research calls, including upgrades for J.C. Penney and Regeneron, a downgrade for Evercore and new coverage of Hasbro.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study

Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study

The outcome of the so-called 'FOURIER' trial is extremely important for Amgen because the data will be used to lobby insurance companies to reimburse for Repatha.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Short Interest Decreases By 22.2% For REGN

Short Interest Decreases By 22.2% For REGN

The most recent short interest data has been released for the 01/13/2017 settlement date, which shows a 594,020 share decrease in total short interest for Regeneron Pharmaceuticals, Inc. , to 2,077,709, a decrease of 22.23% since 12/30/2016.

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Finalists to Compete for Top Awards in Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Forty Of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists

Finalists to Compete for Top Awards in Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.

These Insiders Are Still Finding Some Good Value in the Stock Market

These Insiders Are Still Finding Some Good Value in the Stock Market

Look at what they are buying.

5 Rocket Stocks for 2017 -- Amgen, eBay, More

5 Rocket Stocks for 2017 -- Amgen, eBay, More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow 20,000 came agonizingly close on Friday, but building momentum flagged in the final moments of the trading session.

Dow Teases Wall Street With 20,000 Milestone but Backs Off

Dow Teases Wall Street With 20,000 Milestone but Backs Off

The Dow Jones Industrial Average backs away from its 20,000 milestone again on Friday after coming within a point of the level earlier in the session.

Here's Why Teva Shares Are Plummeting

Here's Why Teva Shares Are Plummeting

Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.